EMA’s CHMP backs Novartis’ Zykadia for first-line use in lung cancer
Zykadia, which is to be subjected orally, is a selective inhibitor of the ALK gene. Capable of combining with other genes to form an abnormal fusion protein, the
Arna Pharma and Slate Run Pharmaceuticals have completed a joint venture (JV) to form a speciality pharmaceutical company in the US focusing on branded products, 505(b)(2) medicines, and specialised generics.